Final report of the phase i trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) radiation therapy oncology group 83-03

Keyphrases

• Neuropathy 100%
• Phase I Trial 100%
• Radiation Therapy Oncology Group 100%
• Hypoxic Cell Radiosensitizer 100%
• Etanidazole 100%
• Area under the Curve 40%
• Toxic Dose 40%
• Increased Incidence 20%
• Neutropenia 20%
• Cumulative Dose 20%
• Neurotoxicity 20%
• Plasma Concentration 20%
• Retrospective Analysis 20%
• Phase II Trial 20%
• Nausea 20%
• Liver Function Tests 20%
• Vomiting 20%
• Radiation Therapy 20%
• Daily Dose 20%
• Drug Exposure 20%
• Intravenous Infusion 20%
• Sensitizer 20%
• Dose-limiting Toxicity 20%
• Hypoxic Cells 20%
• Total Dose 20%
• Unknown Etiology 20%
• Self-limiting 20%
• Misonidazole 20%
• Arthralgia 20%
• Peripheral Sensory Neuropathy 20%
• Pharmacokinetic Parameters 20%
• Skin Rash 20%
• Severe Neuropathy 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Neuropathy 100%
• Radiosensitizing Agent 100%
• Etanidazole 100%
• Neurotoxicity 16%
• Phase II Trials 16%
• Neutropenia 16%
• Nausea and Vomiting 16%
• Rash 16%
• Phase I Trials 16%
• Sensory Neuropathy 16%
• Misonidazole 16%
• Arthralgia 16%
• Pharmacokinetic Parameter 16%